TSXV:THRM - Post Discussion
Post by
Smokey1958 on Sep 20, 2024 12:12pm
Positive Sign
You know there is some desperation in the air when an investor(s) are throwing small numbers of shares of $.075 at the Asks. For a number of reasons there is, arguably, too much momentum to keep a lid on this.
For those concerned about dilution and the current number of outstanding shares there is another angle to look at this. While the share count is definitely high, any substantial amount of revenue* from Venowave should significantly reduce the need for further dilution. The other "hot" irons in the fire are also no longer dilutive as their potential value (in shares) is already part of the current number of outstanding shares.
* What is a reasonable/rational forecast for Venowave sales as measured in units sold?
There are currently over 25 million Americans that suffer from venous insufficiency both medically (ie. varicose veins) and post operatively. Outside of compression stockings and devices where the patient remains static there are few devices that allow the patient to be mobile. Of those Venowave stacks up very well against them.
Be the first to comment on this post